KR102552693B1 - 궤양성 결장염을 치료하는 방법 - Google Patents

궤양성 결장염을 치료하는 방법 Download PDF

Info

Publication number
KR102552693B1
KR102552693B1 KR1020207027982A KR20207027982A KR102552693B1 KR 102552693 B1 KR102552693 B1 KR 102552693B1 KR 1020207027982 A KR1020207027982 A KR 1020207027982A KR 20207027982 A KR20207027982 A KR 20207027982A KR 102552693 B1 KR102552693 B1 KR 102552693B1
Authority
KR
South Korea
Prior art keywords
administered
delete delete
dose
pharmaceutical composition
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207027982A
Other languages
English (en)
Korean (ko)
Other versions
KR20200128101A (ko
Inventor
제임스 베네딕트 캐너번
스튜어트 윌리엄 프리드리히
카트린 앤 크뤼거
캐서린 밀크
제이 로렌스 터틀
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20200128101A publication Critical patent/KR20200128101A/ko
Application granted granted Critical
Publication of KR102552693B1 publication Critical patent/KR102552693B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020207027982A 2018-03-30 2019-03-28 궤양성 결장염을 치료하는 방법 Active KR102552693B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
US62/650,314 2018-03-30
PCT/US2019/024633 WO2019191464A1 (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis

Publications (2)

Publication Number Publication Date
KR20200128101A KR20200128101A (ko) 2020-11-11
KR102552693B1 true KR102552693B1 (ko) 2023-07-07

Family

ID=66429483

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207027982A Active KR102552693B1 (ko) 2018-03-30 2019-03-28 궤양성 결장염을 치료하는 방법

Country Status (29)

Country Link
US (2) US12152072B2 (https=)
EP (2) EP4327866B1 (https=)
JP (4) JP7119114B2 (https=)
KR (1) KR102552693B1 (https=)
CN (1) CN111936165A (https=)
AU (2) AU2019243283C1 (https=)
BR (1) BR112020018099A2 (https=)
CA (1) CA3095297A1 (https=)
DK (2) DK3773715T3 (https=)
EA (1) EA202091989A1 (https=)
ES (2) ES3063700T3 (https=)
FI (2) FI3773715T3 (https=)
HR (2) HRP20240904T1 (https=)
HU (1) HUE067445T2 (https=)
IL (2) IL277514B2 (https=)
LT (2) LT4327866T (https=)
MA (2) MA67901B1 (https=)
MD (1) MD3773715T2 (https=)
MX (1) MX2020010269A (https=)
MY (1) MY202368A (https=)
PL (2) PL3773715T3 (https=)
PT (2) PT3773715T (https=)
RS (2) RS67806B1 (https=)
SG (1) SG11202009526RA (https=)
SI (1) SI3773715T1 (https=)
TW (2) TWI837532B (https=)
UA (1) UA128578C2 (https=)
WO (1) WO2019191464A1 (https=)
ZA (1) ZA202005388B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CA3170677A1 (en) * 2020-02-14 2021-08-19 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
JP2024501900A (ja) * 2021-01-06 2024-01-16 アッヴィ・インコーポレイテッド クローン病及び潰瘍性大腸炎を処置する方法
EP4340875A1 (en) * 2021-05-20 2024-03-27 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP2024521748A (ja) * 2021-05-28 2024-06-04 イーライ リリー アンド カンパニー 潰瘍性大腸炎に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体調節
WO2023095000A1 (en) * 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
US20240199734A1 (en) * 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
KR20250156783A (ko) 2023-03-10 2025-11-03 일라이 릴리 앤드 캄파니 궤양성 결장염을 치료하는 방법
CN121443635A (zh) * 2023-06-16 2026-01-30 信达生物医药科技(杭州)有限公司 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2026060205A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282269A1 (en) 2010-11-04 2012-11-08 Boehringer Ingelheim International Gmbh Anti-IL-23 Antibodies
US20170002060A1 (en) 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006265002B2 (en) * 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
US20110212104A1 (en) * 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
CA3092551A1 (en) * 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282269A1 (en) 2010-11-04 2012-11-08 Boehringer Ingelheim International Gmbh Anti-IL-23 Antibodies
US20170002060A1 (en) 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies

Also Published As

Publication number Publication date
EP4327866A2 (en) 2024-02-28
JP7331219B2 (ja) 2023-08-22
AU2019243283B2 (en) 2023-07-27
JP2025020134A (ja) 2025-02-12
HUE067445T2 (hu) 2024-10-28
AU2023248103B2 (en) 2026-02-05
IL277514B2 (en) 2024-11-01
JP7119114B2 (ja) 2022-08-16
HRP20260275T1 (hr) 2026-04-10
TWI744617B (zh) 2021-11-01
IL312807B1 (en) 2025-02-01
PT4327866T (pt) 2026-02-17
ES3063700T3 (en) 2026-04-20
TW202206104A (zh) 2022-02-16
SI3773715T1 (sl) 2024-06-28
BR112020018099A2 (pt) 2020-12-22
IL312807B2 (en) 2025-06-01
TW201946657A (zh) 2019-12-16
US20210032325A1 (en) 2021-02-04
IL312807A (en) 2024-07-01
EP4327866A3 (en) 2024-03-20
ES2983809T3 (es) 2024-10-24
CA3095297A1 (en) 2019-10-03
IL277514B1 (en) 2024-07-01
RS67806B1 (sr) 2026-03-31
ZA202005388B (en) 2025-05-28
DK3773715T3 (da) 2024-05-27
PL3773715T3 (pl) 2024-08-19
DK4327866T3 (da) 2026-02-23
HRP20240904T1 (hr) 2024-10-11
KR20200128101A (ko) 2020-11-11
PT3773715T (pt) 2024-05-27
US12152072B2 (en) 2024-11-26
EP4327866B1 (en) 2025-12-10
JP7571225B2 (ja) 2024-10-22
FI3773715T3 (fi) 2024-05-30
JP2023166388A (ja) 2023-11-21
LT3773715T (lt) 2024-06-25
RS65661B1 (sr) 2024-07-31
US20250034243A1 (en) 2025-01-30
MY202368A (en) 2024-04-24
EP3773715B1 (en) 2024-05-08
MA52216A (fr) 2021-02-17
CN111936165A (zh) 2020-11-13
AU2019243283A1 (en) 2020-09-24
UA128578C2 (uk) 2024-08-21
AU2019243283C1 (en) 2024-05-02
AU2023248103A1 (en) 2023-11-09
TWI837532B (zh) 2024-04-01
MA67901B1 (fr) 2026-02-27
WO2019191464A1 (en) 2019-10-03
JP2021517156A (ja) 2021-07-15
SG11202009526RA (en) 2020-10-29
MX2020010269A (es) 2020-11-06
LT4327866T (lt) 2026-03-10
FI4327866T3 (fi) 2026-02-18
MD3773715T2 (ro) 2024-10-31
IL277514A (en) 2020-11-30
EA202091989A1 (ru) 2021-01-13
JP2022169562A (ja) 2022-11-09
EP3773715A1 (en) 2021-02-17
PL4327866T3 (pl) 2026-04-20
MA52216B1 (fr) 2024-07-31
NZ767902A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
KR102552693B1 (ko) 궤양성 결장염을 치료하는 방법
JP2023116680A (ja) クローン病を治療する方法に使用するためのミリキズマブ
HK40101440A (en) Mirikizumab in the treatment of ulcerative colitis
HK40036550A (en) Mirikizumab in the treatment of ulcerative colitis
HK40036550B (en) Mirikizumab in the treatment of ulcerative colitis
EA049081B1 (ru) Способы лечения язвенного колита

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20200928

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200928

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221014

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230628

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230703

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230704

End annual number: 3

Start annual number: 1

PG1601 Publication of registration